| scholarly article | Q13442814 |
| P50 | author | Suad Efendic | Q5627647 |
| Kerstin Brismar | Q37376842 | ||
| P2093 | author name string | L Rydén | |
| C Hage | |||
| L Mellbin | |||
| P Lundman | |||
| P2860 | cites work | Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. | Q51486013 |
| The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. | Q51489443 | ||
| Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | Q51497444 | ||
| U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group | Q56914456 | ||
| Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction | Q57484933 | ||
| Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction | Q58447894 | ||
| Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 | ||
| Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria | Q31931889 | ||
| Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes | Q33562235 | ||
| Insulin Secretion in Response to Glycemic Stimulus: Relation of Delayed Initial Release to Carbohydrate intolerance in Mild Diabetes Mellitus* | Q34267205 | ||
| The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus | Q34325421 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card | Q37369367 | ||
| Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. | Q37825946 | ||
| Pathophysiology of prediabetes | Q37833737 | ||
| Sitagliptin: a review | Q37886184 | ||
| Preservation of β-cell function: the key to diabetes prevention | Q37893344 | ||
| Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. | Q40209581 | ||
| Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study | Q40391316 | ||
| Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. | Q40468435 | ||
| The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. | Q40470994 | ||
| Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury | Q43574002 | ||
| Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study | Q43873124 | ||
| Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets | Q44320631 | ||
| Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin | Q44777896 | ||
| Abnormal glucose tolerance--a common risk factor in patients with acute myocardial infarction in comparison with population-based controls | Q45058807 | ||
| Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism | Q45176382 | ||
| Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk | Q46758929 | ||
| Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts | Q46952887 | ||
| Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. | Q51355753 | ||
| Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. | Q51378610 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acute coronary syndrome | Q266018 |
| sitagliptin | Q419832 | ||
| P304 | page(s) | 410-421 | |
| P577 | publication date | 2013-02-14 | |
| P1433 | published in | Journal of Internal Medicine | Q6295387 |
| P1476 | title | Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study. | |
| P478 | volume | 273 |
| Q30240823 | Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. |
| Q38113092 | Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes |
| Q51284461 | Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study. |
| Q38794395 | Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. |
| Q97538758 | Effect of dipeptidyl peptidase-4 inhibitors on complement activation |
| Q34699191 | Incretin-based therapies in prediabetes: Current evidence and future perspectives |
| Q38259933 | Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus |
| Q37279362 | Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance |
| Q58329626 | The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study |
Search more.